Evidence map›Paper›PMID 31413865›Full record

Trial reportRMD open2019

Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis.

Alexandre Virone, Jean-Philippe Bastard, Soraya Fellahi, Jacqueline Capeau, Stéphanie Rouanet, Jean Sibilia, Philippe Ravaud, Francis Berenbaum, Jacques-Eric Gottenberg, Jérémie Sellam

Registry-linked trialOpen access · goldAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in RMD open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01000441 (Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01000441 phase4completednot on this map

Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis

TypeinterventionalSponsorUniversity Hospital, Strasbourg, FranceRan2009 to 2013Enrolled300ConditionsRheumatoid ArthritisArmsinfliximab, etanercept, adalimumab, abatacept, rituximab or tocilizumab
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Adiponectin Deregulation in Systemic Autoimmune Rheumatic Diseases.International journal of molecular sciences · 2021
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Alexandre VironeRheumatology Department, Hôpital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France.ORCID 0000-0003-2955-8449
Jean-Philippe BastardBiochemistry Department, Hôpital Tenon, AP-HP, Paris, France.
Soraya FellahiBiochemistry Department, Hôpital Tenon, AP-HP, Paris, France.
Jacqueline CapeauFaculty of Medicine Sorbonne Université, CRSA INSERM UMRS_938, Paris, France.
Stéphanie RouanetStatEthic, Levallois-Perret, France.
Jean SibiliaRheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Philippe RavaudEpidemiology and Statistics Research Centre, Inserm UMR 1153, Paris Descartes University, Paris, France.
Francis BerenbaumRheumatology Department, Hôpital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France.
Jacques-Eric GottenbergRheumatology Department, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Jérémie SellamRheumatology Department, Hôpital Saint-Antoine, Assistance Publique - Hopitaux de Paris (AP-HP), Paris, France.
Inserm · FRHôpitaux Universitaires de Strasbourg · FRDélégation Paris 5 · FRSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To comparatively investigate the differential effect of second-line tumour necrosis factor inhibitors (TNFis) versus other biological agents on cardiovascular disease (CVD) risk-associated biomarkers in patients with rheumatoid arthritis (RA). Methods: We evaluated the serum levels of lipoprotein-associated apoproteins ApoA1 and ApoB100 and lipoprotein(a) (Lp(a)) and the leptin/adiponectin ratio (LAR) as an insulin resistance proxy in patients with RA from the Rotation Or Change (ROC) trial treated with either a second-line TNFi or another biologic (tocilizumab (TCZ), rituximab or abatacept) at baseline and week 24. We compared the changes in biomarker levels in each group and according to the EULAR response. Results: Of the 300 patients enrolled in the ROC trial, 203 were included in the study, including 96 in the second-line TNFi group and 107 in the other biological group. The measured biomarkers did not deteriorate between baseline and week 24 regardless of the group. A greater improvement in the LAR was noted in the other biological group (median (IQR) -0.12 ng/µg (-0.58 to 0.31) vs 0.04 (-0.19 to 0.43), p=0.033), and a greater improvement in the Lp(a) level was observed following treatment with TCZ than with a TNFi (-0.05 g/L (-0.11 to -0.01) vs -0.01 g/L (-0.02 to 0.01), p<0.001). When considering the patients' responses to treatment, improved biomarkers were mainly observed in the EULAR responders in each treatment group. Conclusions: TNFis and non-TNFis were neutral on improved CVD risk-associated biomarkers in patients with RA insufficiently controlled by TNFis. TCZ could be associated with a better improvement concerning Lp(a) and LAR than TNFis. This improvement could be related to a good therapeutic response, thereby supporting the need of good control of RA. Trial registration number: ClinicalTrials.gov Identifier NCT01000441, registered on 22 October 2009.

Indexed as

AbataceptAdiponectinAgedAntibodies, Monoclonal, HumanizedApolipoprotein A-IApolipoprotein B-100Arthritis, RheumatoidBiological FactorsBiomarkersCardiovascular DiseasesFemaleHumansInsulin ResistanceLeptinLipoprotein(a)MaleAbataceptAdiponectinAntibodies, Monoclonal, HumanizedApolipoprotein A-IApolipoprotein B-100Biological FactorsBiomarkersLeptinLipoprotein(a)RituximabtocilizumabTumor Necrosis Factor Inhibitorsadipokineapolipoproteinbiological agentscardiovascular riskrheumatoid arthritis

Identifiers

PMID31413865
PMCPMC6667971
OpenAlexW2963713343

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.